A Multicenter Adaptive Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Brief description of study
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There are no approved medicines to treat COVID-19. This research is to test an experimental medicine, remdesivir, in adult patients that are hospitalized with COVID-19. The drug has been tested before in humans with other diseases. This research is to see if it is safe and effective in treating patients with COVID-19. Participants will get either remdesivir or a placebo (aninactive medicine), along with the best standard of care for up to 10 days.
Clinical Study Identifier: s20-00286
ClinicalTrials.gov Identifier: NCT04280705
Principal Investigator:
Mark J. Mulligan.
If you are registered as a volunteer, please login to the dashboard to send referrals.